Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Akili Inc's Business Segments
Akili Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Akili Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Endeavor Otc Revenue66.3%
- Endeavor Rx Revenue33.7%
- Collaboration Revenue0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Endeavor Otc Revenue | $ 0 | 66.3% |
| Endeavor Rx Revenue | $ 0 | 33.7% |
| Collaboration Revenue | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Akili Inc
Akili Inc is a digital medicine company that is focused on developing prescription treatments and interventions for cognitive disorders and conditions. The company was founded in 2011 by PureTech Health, a biopharmaceutical company, and is headquartered in Boston, Massachusetts.
Akili primarily utilizes advanced technology and software in order to create digital therapeutics that target specific cognitive functions and brain systems. Their main product is a video game-based platform known as AKL-T01, which is designed to be used as a treatment for pediatric attention deficit hyperactivity disorder (ADHD). The company has also developed other digital therapeutics for conditions like autism spectrum disorder, depression, multiple sclerosis, and traumatic brain injury.
The AKL-T01 platform by Akili is based on the concept of digital biomarkers, which are measurable and objective indicators of cognitive function. This platform combines cognitive science, neuroscience, and entertainment elements in order to create an engaging and impactful treatment experience for patients. Through the use of adaptive algorithms, the video game adapts to the individual's unique capabilities, providing personalized training and therapeutic benefits.
In terms of the ADHD treatment, AKL-T01 is designed to target selected neural systems that are involved in cognitive control, attention, and inhibitory control. The game mechanics and tasks within the game are specifically designed to challenge and improve these cognitive functions, thereby helping patients manage their symptoms of ADHD.
Akili Inc conducts extensive clinical trials to validate the efficacy and safety of their digital therapeutics. They have collaborated with leading academic institutions, research centers, and healthcare providers to conduct rigorous research and gather clinical evidence to support their products. The company has obtained several regulatory clearances, including clearance from the US Food and Drug Administration (FDA) as a novel medical device to treat ADHD.
The long-term vision of Akili Inc is to expand the application of their digital therapeutics to a wide range of cognitive disorders and conditions. They aim to redefine the standards of care in cognitive medicine by providing effective, accessible, and engaging treatments that are scalable and cost-effective. Furthermore, the company envisions a future where their products are integrated into standard care pathways, allowing for personalized and data-driven treatment approaches for patients.
Overall, Akili Inc is at the forefront of digital medicine and is making significant advancements in the field of cognitive therapeutics. Their innovative approach and commitment to evidence-based research are promising for the future of cognitive disorder treatments.
Akili primarily utilizes advanced technology and software in order to create digital therapeutics that target specific cognitive functions and brain systems. Their main product is a video game-based platform known as AKL-T01, which is designed to be used as a treatment for pediatric attention deficit hyperactivity disorder (ADHD). The company has also developed other digital therapeutics for conditions like autism spectrum disorder, depression, multiple sclerosis, and traumatic brain injury.
The AKL-T01 platform by Akili is based on the concept of digital biomarkers, which are measurable and objective indicators of cognitive function. This platform combines cognitive science, neuroscience, and entertainment elements in order to create an engaging and impactful treatment experience for patients. Through the use of adaptive algorithms, the video game adapts to the individual's unique capabilities, providing personalized training and therapeutic benefits.
In terms of the ADHD treatment, AKL-T01 is designed to target selected neural systems that are involved in cognitive control, attention, and inhibitory control. The game mechanics and tasks within the game are specifically designed to challenge and improve these cognitive functions, thereby helping patients manage their symptoms of ADHD.
Akili Inc conducts extensive clinical trials to validate the efficacy and safety of their digital therapeutics. They have collaborated with leading academic institutions, research centers, and healthcare providers to conduct rigorous research and gather clinical evidence to support their products. The company has obtained several regulatory clearances, including clearance from the US Food and Drug Administration (FDA) as a novel medical device to treat ADHD.
The long-term vision of Akili Inc is to expand the application of their digital therapeutics to a wide range of cognitive disorders and conditions. They aim to redefine the standards of care in cognitive medicine by providing effective, accessible, and engaging treatments that are scalable and cost-effective. Furthermore, the company envisions a future where their products are integrated into standard care pathways, allowing for personalized and data-driven treatment approaches for patients.
Overall, Akili Inc is at the forefront of digital medicine and is making significant advancements in the field of cognitive therapeutics. Their innovative approach and commitment to evidence-based research are promising for the future of cognitive disorder treatments.
Akili Inc. is a pioneering digital medicine company that develops innovative therapeutic solutions designed to address cognitive impairments resulting from various conditions, particularly neurodevelopmental disorders. Through the application of rigorous scientific research and advanced technology, Akili focuses on creating immersive and engaging digital experiences that can effectively improve cognitive functioning.
Segments
1. Cognitive Health Solutions:
Akili operates primarily in the cognitive health sector, targeting conditions such as Attention-Deficit/Hyperactivity Disorder (ADHD) and other cognitive deficits. This segment is dedicated to enhancing cognitive performance through digital interventions that leverage gaming technology.
2. Digital Therapeutics:
Within this segment, Akili develops clinically validated digital therapeutics that can be prescribed by healthcare professionals. These digital medications are designed to be integrated with traditional treatment plans, providing a complementary approach to cognitive therapy and support.
3. Research and Development:
Akili engages in ongoing research to refine its products and explore new therapeutic possibilities. This segment is critical for staying at the forefront of digital medicine and ensuring that their offerings meet safety and efficacy standards.
Products
1. Akili’s Lead Product – EndeavorRx:
EndeavorRx is Akilis flagship product, recognized as the first prescription video game for children with ADHD. It is designed to improve attention function through an engaging, interactive experience. The games design targets cognitive challenges associated with ADHD by utilizing adaptive gameplay that adjusts to the users performance, thereby promoting cognitive engagement and skill development.
2. Research Products:
Akili continues to develop additional digital therapeutics aimed at various demographic segments, including different age groups and disorders. These products are still under research and development but aim to extend the benefits of digital cognitive interventions beyond ADHD.
Services
1. Clinical Support Services:
Akili provides support for healthcare professionals by offering comprehensive educational resources and clinical insights into the integration of their digital therapeutics into existing treatment regimens. This may include training on how to prescribe EndeavorRx and follow-up mechanisms to monitor patient progress.
2. Patient Engagement Programs:
Akilis services extend to patient engagement, offering tools and support systems for patients and their families to facilitate the use of their digital therapies. This includes user guides, progress tracking features, and feedback loops to improve user experience.
3. Data Collection and Analytics:
Akili is invested in maintaining robust data analytics capabilities to monitor the effectiveness of its products. They often engage in studies and clinical trials to gather real-world evidence that supports their therapeutic claims and to inform future product development.
4. Partnerships with Healthcare Providers:
The company actively collaborates with healthcare organizations and professionals to promote awareness of digital therapeutics. This collaboration aims to integrate Akili’s products into broader treatment protocols and clinical practice, enhancing the network of support around patients using their therapies.
Conclusion
Akili Inc. is positioned at the intersection of healthcare and technology, focusing on addressing cognitive issues through innovative digital solutions. With an emphasis on research, development, and clinical integration, Akili continues to expand its impact in the realm of cognitive health and digital therapeutics. The companys unique offerings not only enhance therapeutic interventions for conditions like ADHD but also foster a growing understanding of the role of digital tools in traditional healthcare settings.
Segments
1. Cognitive Health Solutions:
Akili operates primarily in the cognitive health sector, targeting conditions such as Attention-Deficit/Hyperactivity Disorder (ADHD) and other cognitive deficits. This segment is dedicated to enhancing cognitive performance through digital interventions that leverage gaming technology.
2. Digital Therapeutics:
Within this segment, Akili develops clinically validated digital therapeutics that can be prescribed by healthcare professionals. These digital medications are designed to be integrated with traditional treatment plans, providing a complementary approach to cognitive therapy and support.
3. Research and Development:
Akili engages in ongoing research to refine its products and explore new therapeutic possibilities. This segment is critical for staying at the forefront of digital medicine and ensuring that their offerings meet safety and efficacy standards.
Products
1. Akili’s Lead Product – EndeavorRx:
EndeavorRx is Akilis flagship product, recognized as the first prescription video game for children with ADHD. It is designed to improve attention function through an engaging, interactive experience. The games design targets cognitive challenges associated with ADHD by utilizing adaptive gameplay that adjusts to the users performance, thereby promoting cognitive engagement and skill development.
2. Research Products:
Akili continues to develop additional digital therapeutics aimed at various demographic segments, including different age groups and disorders. These products are still under research and development but aim to extend the benefits of digital cognitive interventions beyond ADHD.
Services
1. Clinical Support Services:
Akili provides support for healthcare professionals by offering comprehensive educational resources and clinical insights into the integration of their digital therapeutics into existing treatment regimens. This may include training on how to prescribe EndeavorRx and follow-up mechanisms to monitor patient progress.
2. Patient Engagement Programs:
Akilis services extend to patient engagement, offering tools and support systems for patients and their families to facilitate the use of their digital therapies. This includes user guides, progress tracking features, and feedback loops to improve user experience.
3. Data Collection and Analytics:
Akili is invested in maintaining robust data analytics capabilities to monitor the effectiveness of its products. They often engage in studies and clinical trials to gather real-world evidence that supports their therapeutic claims and to inform future product development.
4. Partnerships with Healthcare Providers:
The company actively collaborates with healthcare organizations and professionals to promote awareness of digital therapeutics. This collaboration aims to integrate Akili’s products into broader treatment protocols and clinical practice, enhancing the network of support around patients using their therapies.
Conclusion
Akili Inc. is positioned at the intersection of healthcare and technology, focusing on addressing cognitive issues through innovative digital solutions. With an emphasis on research, development, and clinical integration, Akili continues to expand its impact in the realm of cognitive health and digital therapeutics. The companys unique offerings not only enhance therapeutic interventions for conditions like ADHD but also foster a growing understanding of the role of digital tools in traditional healthcare settings.